Below are the most recent publications written about "Sodium" by people in Profiles.
-
Duan HY, Barajas-Martinez H, Antzelevitch C, Hu D. The potential anti-arrhythmic effect of SGLT2 inhibitors. Cardiovasc Diabetol. 2024 07 15; 23(1):252.
-
Hamaya R, Wang M, Juraschek SP, Mukamal KJ, Manson JE, Tobias DK, Sun Q, Curhan GC, Willett WC, Rimm EB, Cook NR. Prediction of 24-Hour Urinary Sodium Excretion Using Machine-Learning Algorithms. J Am Heart Assoc. 2024 May 21; 13(10):e034310.
-
Lin TY, Kang EY, Shao SC, Lai EC, Wang NK, Garg SJ, Chen KJ, Kang JH, Wu WC, Lai CC, Hwang YS. Association of sodium-glucose cotransporter-2 inhibitors and the risk of retinal vascular occlusion: A real-world retrospective cohort study in Taiwan. Diabetes Metab Res Rev. 2024 Feb; 40(2):e3773.
-
Ramos Gonzalez M, Axler MR, Kaseman KE, Lobene AJ, Farquhar WB, Witman MA, Kirkman DL, Lennon SL. Melatonin supplementation does not alter vascular function or oxidative stress in healthy normotensive adults on a high sodium diet. Physiol Rep. 2023 Dec; 11(24):e15896.
-
Huang Y, Wang LL, Liu ZB, Chen C, Ren X, Luo AT, Ma JH, Antzelevitch C, Barajas-Mart?nez H, Hu D. Underlying mechanism of atrial fibrillation-associated Nppa-I137T mutation and cardiac effect of potential drug therapy. Heart Rhythm. 2024 02; 21(2):184-196.
-
Belanger MJ, Kovell LC, Turkson-Ocran RA, Mukamal KJ, Liu X, Appel LJ, Miller ER, Sacks FM, Christenson RH, Rebuck H, Chang AR, Juraschek SP. Effects of the Dietary Approaches to Stop Hypertension Diet on Change in Cardiac Biomarkers Over Time: Results From the DASH-Sodium Trial. J Am Heart Assoc. 2023 01 17; 12(2):e026684.
-
Stencel J, Rajapreyar I, Samson R, Le Jemtel T. Comprehensive and Safe Decongestion in Acutely Decompensated Heart Failure. Curr Heart Fail Rep. 2022 10; 19(5):364-374.
-
Sahai SK, Balonov K, Bentov N, Bierle DMM, Browning LM, Cummings KC, Dougan BM, Maxwell M, Merli GJ, Oprea AD, Sweitzer B, Mauck KF, Urman RD. Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Mayo Clin Proc. 2022 09; 97(9):1734-1751.
-
Moellmann J, Mann PA, Kappel BA, Kahles F, Klinkhammer BM, Boor P, Kramann R, Ghesquiere B, Lebherz C, Marx N, Lehrke M. The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis. Diabetes Obes Metab. 2022 11; 24(11):2263-2272.
-
Cappuccio FP, Campbell NRC, He FJ, Jacobson MF, MacGregor GA, Antman E, Appel LJ, Arcand J, Blanco-Metzler A, Cook NR, Guichon JR, L'Abb? MR, Lackland DT, Lang T, McLean RM, Miglinas M, Mitchell I, Sacks FM, Sever PS, Stampfer M, Strazzullo P, Sunman W, Webster J, Whelton PK, Willett W. Sodium and Health: Old Myths and a Controversy Based on Denial. Curr Nutr Rep. 2022 06; 11(2):172-184.